Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion.
Kaartinen T, Luostarinen A, Maliniemi P, Keto J, Arvas M, Belt H, Koponen J, Mäkinen PI, Loskog A, Mustjoki S, Porkka K, Ylä-Herttuala S, Korhonen M. Kaartinen T, et al. Among authors: loskog a. Cytotherapy. 2017 Sep;19(9):1130. doi: 10.1016/j.jcyt.2017.06.003. Epub 2017 Jun 20. Cytotherapy. 2017. PMID: 28645733 No abstract available.
The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses.
Christiansson L, Söderlund S, Mangsbo S, Hjorth-Hansen H, Höglund M, Markevärn B, Richter J, Stenke L, Mustjoki S, Loskog A, Olsson-Strömberg U. Christiansson L, et al. Among authors: loskog a. Mol Cancer Ther. 2015 May;14(5):1181-91. doi: 10.1158/1535-7163.MCT-14-0849. Epub 2015 Mar 11. Mol Cancer Ther. 2015. PMID: 25761894
Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion.
Kaartinen T, Luostarinen A, Maliniemi P, Keto J, Arvas M, Belt H, Koponen J, Mäkinen PI, Loskog A, Mustjoki S, Porkka K, Ylä-Herttuala S, Korhonen M. Kaartinen T, et al. Among authors: loskog a. Cytotherapy. 2017 Jun;19(6):689-702. doi: 10.1016/j.jcyt.2017.03.067. Epub 2017 Apr 11. Cytotherapy. 2017. PMID: 28411126 Free article.
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma.
Rowinsky EK, Paner A, Berdeja JG, Paba-Prada C, Venugopal P, Porkka K, Gullbo J, Linder S, Loskog A, Richardson PG, Landgren O. Rowinsky EK, et al. Among authors: loskog a. Invest New Drugs. 2020 Oct;38(5):1448-1453. doi: 10.1007/s10637-020-00915-4. Epub 2020 Mar 3. Invest New Drugs. 2020. PMID: 32125598 Free PMC article. Clinical Trial.
Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors.
Karlsson H, Svensson E, Gigg C, Jarvius M, Olsson-Strömberg U, Savoldo B, Dotti G, Loskog A. Karlsson H, et al. Among authors: loskog a. PLoS One. 2015 Dec 23;10(12):e0144787. doi: 10.1371/journal.pone.0144787. eCollection 2015. PLoS One. 2015. PMID: 26700307 Free PMC article.
Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients.
Hoffmann JM, Schubert ML, Wang L, Hückelhoven A, Sellner L, Stock S, Schmitt A, Kleist C, Gern U, Loskog A, Wuchter P, Hofmann S, Ho AD, Müller-Tidow C, Dreger P, Schmitt M. Hoffmann JM, et al. Among authors: loskog a. Front Immunol. 2018 Jan 10;8:1956. doi: 10.3389/fimmu.2017.01956. eCollection 2017. Front Immunol. 2018. PMID: 29375575 Free PMC article.
86 results